Primer Mesane Lenfoması: Olgu Sunumu

Year 2020, Volume: 15 Issue: 1, 51 - 55, 26.02.2020

Mehmet Sevim , Bekir Aras , Şahin Kabay

https://doi.org/10.33719/yud.639544

https://izlik.org/JA44JY34DL

Abstract

Mesane karsinomu üriner sistemin en sık görülen tümörüdür. Malign mesane kanserlerinin% 90'dan fazlası, transizyonel hücreli tümörlerdir. Mesanenin transizyonel olmayan tümörleri tüm mesane tümörlerinin% 5-7'sini oluşturur; % 3'ünü skuamöz hücreli karsinom,% 2 adenokarsinom,% 1 undiferansiye karsinom ve daha nadiren küçük hücreli karsinom ve lenfomadır. Mesanenin primer lenfoması çok nadir görülür. Nadir olmasına rağmen, bu tümörler ürologlar tarafından akılda tutulmalı ve sıradışı mesane kitlelerinde düşünülmelidir. Bu yazıda mesane tümörü ön tanısı ile ameliyat edilen ve patolojisi primer mesane lenfoması olan olguya yaklaşımımızı literatür bilgileri eşliğinde sunuyoruz.

Keywords

marjinal zon lenfoma , mesane kanseri , pozitron emisyon tomografisi

Primary Bladder Lymphoma: Case Report

https://izlik.org/JA44JY34DL

Abstract

Bladder carcinoma is
the most common tumor of the urinary system. More than 90 % of malignant
bladder cancers are transitional cell tumors. Non-transitional tumors of the
bladder account for 5-7 % of all bladder tumors; 3 % squamous cell carcinoma, 2
% adenocarcinoma, 1 % indifferentiated carcinoma and, more rarely, small cell
carcinomas and lymphoma. Primary lymphoma of the bladder is very rare. Although
rare these tumors should be kept in mind by urologists and should be considered
in unusual bladder masses. In this
article, we present a case of primary bladder lymphoma who was operated with a
preliminary diagnosis of bladder tumor.

Keywords

Marginal zone lymphoma , Bladder cancer , Positron emission tomography

References

• 1) Fortuny J, Kogevinas M, Chang-Claude J, et al. Tobacco, occupation and non-transitional-cell carcinoma of the bladder: an international case-control study. Int J Cancer 1999;80:44-6.
• 2) Manunta A, Vincendeau S, Kırıkakou G, et al. Non-transitional cell bladder carcinomas. BJU international 2005;95:497-502
• 3) Bray F, Ren JS, Masuyer E, Ferlay J. Global estimates of cancer prevalence for 27 sites in the adult population in 2008. Int J Cancer 2013;132:1133-45.
• 4) Bates AW et al. (2000) Malignant lymphoma of the urinary bladder: a clinicopathological study of 11 cases. J Clin Pathol 53: 458–461
• 5) Kuhara H, Tamura Z, Suchi T, Hattori R and Kinukawa T: Primary malignant lymphoma of the urinary bladder: A case report. Acta Pathol Jpn 40: 764-769, 1990.
• 6) Horasanli, Kaya, et al. "A case of primary lymphoma of the bladder managed with multimodal therapy." Nature Reviews Urology 5.3 (2008): 167.
• 7) Hughes M, Morrison A and Jackson R: Primary bladder lymphoma: Management and outcome of 12 patients with a review of the literature. Leuk Lymphoma 46: 873-877, 2005.
• 8) Ohsawa M, Aozasa K, Horiuchi K, Kanamaru A. Malignant lymphoma of bladder. Report of three cases and review of the literature. Cancer 1993; 72: 1969-74.
• 9) Kempton CL, Kurtin PJ, Inwards DJ, Wollan P, Bostwick DG. Malignant lymphoma of the bladder: evidence from 36 cases that low-grade lymphoma of the MALT-type is the most common primary bladder lymphoma. Am J Surg Pathol 1997;21:1324.
• 10) Oscier D, Bramble J, Hodges E and Wright D: Regression of mucosa-associated lymphoid tissue lymphoma of the bladder after antibiotic therapy. J Clin Oncol 20: 882, 2000.
• 11) Montalban C, Santon A, Boixeda D, Redondo C, Alvarez I, Calleja JL de Argilla CM and Bellas C: Treatment of low-grade gastric mucosa associated lymphoid tissue lymphoma in stage I with Helicobacter pylori eradication: Long-term results after sequential histologic and molecular follow-up. Haematologica 86: 609-617, 2001.
• 12) Liu H, Ruskon-Fourmestraux A, Lavergne-Slove A, Ye H, Molina T, Bouhnik Y, Hamoudi RA, Diss TC, Dogan A, Megraud F, Rambaud JC, Du MQ and Isaacson PG: Resistance of t(11;18) positive gastric mucosa-associated lymphoid tissue lymphoma to Helicobacter pylori eradication therapy. Lancet 357: 39-40, 2001.
• 13) Raderer M, Wohrer S, Bartsch R, Prager G, Drach J, Hejna M, Gaiger A, Turetschek K, Jaeger U, Streubel B and Zielinski CC: Phase II study of oxaliplatin for treatment of patients with mucosa-associated lymphoid tissue lymphoma. J Clin Oncol 23: 8442-8446, 2005.
• 14) National Cancer Institute sponsored study of classifications of non-hodgkin’s lymphomas: Summary and description of a working formulation for clinical usage. Cancer; 49: 2112-35, 1982.
• 15) Simpson RHW, Bridger JE, Anthony PP, et al: Malignant lymphoma of the lower urinary tract: A clinicopathologic study with review of literature. Br J Urol; 65: 254-60, 1990).
• 16) Al-Maghrabi J, Kamel Reid S, Jewett M, et al: Primary low grade B-cell lymphoma of mucosa-associated lymphoid tissue type (MALT). Arch Pathol Lab Med; 125: 332-36, 2001.
• 17) Elstrom R, Guan L, Baker G: Utility of FDG-PET scanning in lymphoma by WHO classification, Blood; 101: 3875-3876, 2003.
• 18) Tsang RW1, Gospodarowicz MK, Pintilie M, Bezjak A, Wells W, Hodgson DC, Crump M. Stage I and II MALT lymphoma: results of treatment with radiotherapy. Int J Radiat Oncol Biol Phys. 2001 Aug 1;50(5):1258-64.